This clinical trial is focused on studying the treatment of deep partial and full-thickness burns. The treatment being tested is called denovoSkin™, which is a special type of skin graft. This skin graft is made from a bilayer engineered collagen hydrogel that includes the patient’s own skin cells, specifically keratinocytes and fibroblasts. These are types of cells that play a crucial role in skin repair and regeneration. The purpose of the study is to confirm how effective and safe this new treatment is for helping wounds heal and reducing scarring compared to the standard skin grafting method.

During the study, patients will receive the denovoSkin™ treatment, and their progress will be monitored over time. The study will look at how well the wounds close and how much scarring occurs after the treatment. The treatment involves implanting the skin graft onto the burn area, and the healing process will be observed at various intervals, such as 10 weeks, 3 months, and 6 months after the grafting. The study will also assess the quality of the skin and any potential infections at the grafted sites.

The trial aims to provide valuable information on whether denovoSkin™ can be a better option for patients with severe burns, offering improved healing and less scarring. This research could lead to advancements in burn treatment, providing new hope for those affected by serious burn injuries. The study is expected to continue until 2028, allowing for comprehensive data collection and analysis.